Minerva Neurosciences Announces Update for Three Clinical Trials
Minerva Neurosciences, Inc (NERV)
Last minerva neurosciences, inc earnings: 3/9 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.minervaneurosciences.com/investor-relations
Company Research
Source: GlobeNewswire
WALTHAM, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced an update on three clinical-stage programs with roluperidone (MIN-101), seltorexant (MIN-202) and MIN-117. The Company will hold a conference call at 8:30 a.m. today to discuss these programs (see dial-in information below). Roluperidone: A total of 384 patients of a target total number of 501 patients have been enrolled into the ongoing Phase 3 trial with roluperidone to treat negative symptoms in schizophrenia, and there are currently 33 patients in screening. Due to a cyber-attack on one of the Company’s external contractors that resulted in a disruption to patient recruitment in the study, the Company now expects to complete enrollment at approximately year-end and anticipates top-line results from the 12-week, double-blind portion of the
Show less
Read more
Impact Snapshot
Event Time:
NERV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NERV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NERV alerts
High impacting Minerva Neurosciences, Inc news events
Weekly update
A roundup of the hottest topics
NERV
News
- Minerva Neurosciences, Inc. (NASDAQ: NERV) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Minerva Neurosciences, Inc. (NASDAQ: NERV) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Minerva Neurosciences, Inc. (NASDAQ: NERV) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Minerva Neurosciences, Inc. (NASDAQ: NERV) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Minerva Neurosciences, Inc. (NASDAQ: NERV) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
NERV
Earnings
- 11/5/24 - Beat
NERV
Analyst Actions
- 11/6/24 - HC Wainwright
NERV
Sec Filings
- 12/6/24 - Form 4
- 12/6/24 - Form 4
- 12/6/24 - Form 4
- NERV's page on the SEC website